Regulatory
Pfizer to Seek Litfulo Approval for Vitiligo After Two Positive Phase 3 Trials
The oral immunology drug ritlecitinib hit its co-primary endpoints in the TRANQUILLO studies, setting up filings for nonsegmental vitiligo, a condition with no approved oral therapy.